Navigation Links
First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
Date:8/27/2007

y anti-apoptotic proteins such as XIAP. Loss of activity of these proteins restores the ability of chemoresistant tumour cells to undergo apoptosis in response to chemotherapy. The putative molecular target for phenoxodiol is a tumour-specific protein, accounting for the highly selective nature of the drug.

About Marshall Edwards, Inc.: Marshall Edwards, Inc. (Nasdaq: MSHL) is a specialist oncology company focused on the clinical development of novel anti- cancer therapeutics. These derive from a flavonoid technology platform which has generated a number of novel compounds characterised by broad ranging efficacy against a range of cancer targets with few side effects. The unique combination of efficacy and safety has been explained by their ability to target an enzyme present on the surface of cancer cells, thereby inhibiting the production of pro-survival proteins within the cell. Marshall Edwards, Inc., has licensed rights from Novogen Limited (ASX: Novogen - Nasdaq: NVGN) to bring three oncology drugs - phenoxodiol, NV-196 and NV-143 - to market globally. Marshall Edwards, Inc., is majority owned by Novogen, an Australian biotechnology company that is specialising in the development of therapeutics based on a flavonoid technology platform. Novogen, based in Sydney, Australia, is developing a range of therapeutics across the fields of oncology, cardiovascular disease and inflammatory diseases. More information on phenoxodiol and on the Novogen group of companies can be found at and http://www.novogen.com .

(1) Piura B and Meirovitz M. Weekly single-agent carboplatin in heavily

pretreated patients with recurrent ovarian, peritoneal and fallopian


'/>"/>

SOURCE Novogen Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
3. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
4. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
5. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
6. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
7. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
10. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
11. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... , Aug. 1, 2014 MGC ... technologies company, announced today that it has completed ... manufacturer of cardiorespiratory diagnostic products based in Sorinnes, ... has served the European cardiorespiratory diagnostics market since ... revenues of approximately €4.7 million ($6.3 million) and ...
(Date:8/1/2014)... 1, 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: ... technologies are used to develop, manufacture and sell enzymes ... and industrial enzyme industries, announced today that it will ... June 30, 2014 after market close on Thursday, August ... day at 5:00 p.m. Eastern Time to discuss those ...
(Date:7/31/2014)... , July 31, 2014  Sorrento Therapeutics, Inc. (NASDAQ: ... Mr. Amar Singh , Chief Business Officer and Executive ... natural causes on July 30. "Sorrento is deeply ... and colleague. Our immediate thoughts go to Amar,s family and ... Chief Executive Officer. Mr. Singh joined Sorrento ...
Breaking Medicine Technology:MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 2MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 3MGC Diagnostics Corporation Completes Acquisition of MediSoft SA 4Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3Sorrento Announces the Unexpected Death of its Chief Business Officer 2
... Research Group (MRG), the global authority on medical ... over $30 million in 2010. Revenues, however, remained ... prices and greater market penetration of refurbished scopes. ... manufacturers are being forced to promote creative options ...
... MORRISTOWN, N.J., Oct. 27 Watson Pharmaceuticals, Inc. (NYSE: ... Watson Laboratories, Inc., filed a new drug application under ... Act (FFDCA) with the U.S. Food and Drug Administration ... 20 and 40 mg tablets.  Watson,s rosuvastatin zinc tablets ...
Cached Medicine Technology:Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 2Despite Rising Procedure Volumes, the $30 Million European Arthroscope Market Experienced Nominal Growth in 2010 3Watson Confirms Crestor® Patent Challenge 2
(Date:8/1/2014)... School of Medicine in St. Louis helps explain why ... are more harmful than similar tumors in females. For ... diagnosed twice as often in males, who suffer greater ... long. , The researchers found that retinoblastoma protein (RB), ... less active in male brain cells than in female ...
(Date:8/1/2014)... The U.S. Food and Drug Administration announced on Friday ... fight type 2 diabetes. Jardiance (empagliflozin) "can ... to control blood sugar levels in the overall management ... of Drug Evaluation II in the FDA,s Center for ... The FDA also recommended that Jardiance be used ...
(Date:8/1/2014)... The evolving healthcare landscape presents ... At ThoughtSpot 2014, AmerisourceBergen and Good Neighbor Pharmacy’s ... resources to enhance patient care and profitability. At ... issues to give independent pharmacists the tools they ... ThoughtSpot show attendance experienced a nearly 70% increase ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... 2014 (HealthDay News) -- Patients with the progressive, deadly ... have a new weapon to battle the disease, the ... The agency approved a new treatment, an inhaled spray ... killer of Americans. COPD, which is often linked to ... and emphysema. Patients with COPD may experience ...
Breaking Medicine News(10 mins):Health News:Study reveals one reason brain tumors are more common in men 2Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2
... ROCK, Ark., Oct. 20 Heifer International, http://www.heifer.org, ... gift alternative for the green-minded client, the hard-to-shop-for,person ... tighter gift budgets.,Heifer focuses on doing one thing ... billion people living on less than $2 a ...
... Ride Home" , ... Alameda, California (PRWEB) October 20, 2008 -- Alameda-based ... of holidays for the Safe and Sober Free Cab Ride Home program. ... in Alameda and Luxor Cab in San Francisco to provide free transportation ...
... for treatment for GERD and Erosive ... Esophagitis, ... that Takeda Global Research and,Development Center, Inc., a wholly owned United States ... agency will not be able to complete its review of the TAK-390MR ...
... Young Throats, FARMINGDALE, N.Y., Oct. 18 ... Group, Ltd. (IBG), a manufacturer,of innovative sports and ... Throat Cooler(R). This non-medicated ready-to-freeze,liquid product is a ... a 100%,drug free product to help hydrate and ...
... approximately one,in eight couples of childbearing age are infertile, ... specialist for help trying to conceive,(source: CDC)., Conceive ... who,wants to keep herself healthy so she can achieve ... are thinking about family building,and the new special issue, ...
... CALGARY, Oct. 17 /PRNewswire-FirstCall/ - The Westaim ... between its wholly owned,subsidiary iFire Technology Ltd. ... will sell its equipment, patents and intellectual ... The sale is subject to,several conditions, including ...
Cached Medicine News:Health News:Heifer International: The Greener Good for Holiday Giving 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 2Health News:Free Cab Rides Home for Halloween in Alameda, Oakland, Berkeley and San Francisco, California 3Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 2Health News:Integrated Beverage Group Launches Children's Throat Cooler(R) 3Health News:Conceive Magazine Introduces a Special Issue: 'The Birds, The Bees, and Modern Medicine' 2Health News:Westaim announces sale of iFire Technology Ltd. assets 2
... Tip Laryngoscopes are the most ... The articulating tip aids during ... improved view of epiglottis. Available ... styles. We guarantee your complete ...
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
Medicine Products: